Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Kathleen Hawker"'
Autor:
Gina M. Remington, Katherine Treadaway, Teresa Frohman, Amber Salter, Olaf Stüve, Michael K. Racke, Kathleen Hawker, Federica Agosta, Maria Pia Sormani, Massimo Filippi, Elliot M. Frohman
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 3 (2010)
Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combina
Externí odkaz:
https://doaj.org/article/cfc0234771e54308bfbddeeaf2f61dc0
Autor:
Ilya Kister, Yury Patskovsky, Ryan Curtin, Jinglan Pei, Katherine Perdomo, Zoe Rimler, Iryna Voloshyna, Marie I. Samanovic, Amber R. Cornelius, Yogambigai Velmurugu, Samantha Nyovanie, Joseph J. Kim, Ethan Tardio, Tamar E. Bacon, Lana Zhovtis Ryerson, Pranil Raut, Rosetta Pedotti, Kathleen Hawker, Catarina Raposo, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Mark J. Mulligan, Michelle Krogsgaard, Gregg J. Silverman
ObjectiveTo determine the impact of MS disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to SARS-CoV-2 infection.MethodsMS patients aged 18-60 were evaluated for anti-nucleocapsid and anti-Spike RBD antibody with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07123a16a2d5d1d7243ba7e641329812
https://doi.org/10.1101/2022.01.10.22268752
https://doi.org/10.1101/2022.01.10.22268752
Publikováno v:
Multiple Sclerosis and Related Disorders. 8:124-130
Fingolimod is a once-daily, orally administered therapy for relapsing forms of MS. It has been shown to reduce relapse rates significantly in all phase II and phase III clinical trials when compared with placebo and intramuscular interferon β-1a (IF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b91ea1bb37abe4f251691eee80d2538
Autor:
Kathleen Hawker
Publikováno v:
Neurologic Clinics. 29:423-434
Progressive multiple sclerosis (MS) consists of 3 phenotypic subtypes: secondary progressive MS, primary progressive MS, and progressive relapsing MS. There has been a paucity of approved treatments for these subtypes possibly driven by irreversible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ac8e303525940ea32860b1eff98ff7
https://doi.org/10.1016/j.ncl.2011.01.002
https://doi.org/10.1016/j.ncl.2011.01.002
Autor:
Kathleen Hawker
Publikováno v:
CONTINUUM: Lifelong Learning in Neurology. 16:211-225
Primary progressive multiple sclerosis (MS), comprising 10% to 15% of all cases of MS, is characterized by an insidious progression from the onset of disease, making it clinically distinct from the commonest form, relapsing remitting MS. Making the d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8a1f9125d8ac189eecc103ca6998fa1
https://doi.org/10.1212/01.con.0000389943.81981.3b
https://doi.org/10.1212/01.con.0000389943.81981.3b
Autor:
Teresa C. Frohman, Maria Pia Sormani, Michael K. Racke, Elliot M. Frohman, Federica Agosta, Katherine Treadaway, Massimo Filippi, Olaf Stüve, Gina Remington, Kathleen Hawker, Amber Salter
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 3 (2010)
Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f1a5c75f20502a0ebf135a673e4b8f3
https://doi.org/10.1177/1756285609355851
https://doi.org/10.1177/1756285609355851
Publikováno v:
Expert review of neurotherapeutics. 16(1)
Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23658861b15de0295a6abf61b8b2226b
https://pubmed.ncbi.nlm.nih.gov/26587577
https://pubmed.ncbi.nlm.nih.gov/26587577
Autor:
Elliot M. Frohman, Michael K. Racke, J. T. Phillips, Sherry Alexander, D. Sims, Kathleen Hawker, S. O'Leary, K. Brannon
Publikováno v:
Multiple Sclerosis Journal. 10:302-307
Background: The objective for this article is to highlight some of the adverse skin manifestations associated with injectable disease modifying therapy for multiple sclerosis (MS). Early identification and intervention can often lead to minimal conse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c643a3c0aa9be966c4f2b3e3d333e3e
https://doi.org/10.1191/1352458504ms1002oa
https://doi.org/10.1191/1352458504ms1002oa
Autor:
Kathleen, Hawker, Elliot, Frohman
Publikováno v:
Primary Care: Clinics in Office Practice. 31:201-226
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b710f0f82f5f57bcb1be8f68885c4244
https://doi.org/10.1016/s0095-4543(03)00123-4
https://doi.org/10.1016/s0095-4543(03)00123-4
Publikováno v:
Clinical Neuropharmacology. 27:80-83
Objective To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS). Background MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5'-monophosphate dehydrogenase type II, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a540d4626417d34eafee6945821e5bc7
https://doi.org/10.1097/00002826-200403000-00006
https://doi.org/10.1097/00002826-200403000-00006